Q&A
Retatrutide: Frequently Asked Questions
Answers drawn from the published trial record. Where the data are incomplete, the gap is stated plainly.
What cardiovascular and kidney outcomes is retatrutide being evaluated for in Phase 3?
TRIUMPH-3 (NCT05882045) evaluates retatrutide in participants with obesity and established cardiovascular disease [9]. A separate trial (NCT06383390) is a dedicated cardiovascular and kidney outcomes study [10]. Additional Phase 3 arms address type 2 diabetes and chronic kidney disease (TRANSCEND-CKD). Results from all of these trials are pending as of mid-2026.
What does retatrutide do?
Retatrutide simultaneously activates three hormone receptors — GLP-1R (appetite suppression + insulin), GIPR (insulin augmentation + adipose effects), and GCGR (energy expenditure + hepatic fat breakdown) — producing combined effects larger than any dual or single agonist studied previously. In Phase 2, the highest dose produced −24.2% body weight, −2.02% HbA1c in T2D participants, and −82.4% liver fat in the MASLD substudy [1][2][5].
How does retatrutide work?
Retatrutide binds and activates GLP-1R, GIPR, and GCGR simultaneously via its engineered peptide sequence [3]. The GLP-1 arm reduces appetite and stimulates glucose-dependent insulin secretion. The GIP arm augments the insulin signal and targets adipose tissue. The glucagon arm increases energy expenditure and drives hepatic lipid metabolism. The combination of reduced intake, improved glucose handling, and increased calorie burn is what produces the larger weight-loss signal versus single or dual agonists [6].
How to reconstitute retatrutide?
There is no published reconstitution protocol for retatrutide. In clinical trials it was supplied by Eli Lilly as a pre-prepared solution for injection — not reconstituted on site. No approved formulation standard exists. Gray-market vials requiring reconstitution have no validated protocol, no verified purity, and no sterility assurance [1].
Is retatrutide FDA approved?
No. Retatrutide is not FDA-approved and is not approved by any regulatory agency as of mid-2026. It is in Phase 3 clinical trials. A 2025 systematic review confirms its active Phase 3 status alongside 13 other agents in the anti-obesity pipeline, none of which have yet reported pivotal outcomes [7]. No NDA has been submitted.
When will retatrutide be available?
No regulatory submission timeline has been announced by Eli Lilly as of mid-2026. Phase 3 TRIUMPH trials are ongoing. Analogous agents in the incretin class have required 3–5 years from Phase 3 initiation to potential approval. The 2025 systematic review notes retatrutide as among the most advanced agents in the pipeline, but all timelines are contingent on trial outcomes and the FDA review process [7].
How to take retatrutide?
In Phase 2 trials, retatrutide was administered as a subcutaneous (under-skin) injection once weekly [1][2]. This is how it was studied in a clinical-trial setting under medical supervision. No prescribing guidance exists — the compound is not approved and is not available as a prescription product. This site does not provide dosing instructions.
How long does retatrutide take to work?
In Phase 2 trials, significant weight loss was observed within the first 4–8 weeks of treatment. A 2025 review synthesizes Phase 1/2 data, noting the ~24% weight-loss trajectory — which emerged progressively over the 48-week trial period — as a step-change versus prior incretin therapies [6]. The Phase 1b trial observed meaningful weight and glucose reductions within 12 weeks at higher doses [4].
Is retatrutide better than tirzepatide?
Phase 2 head-to-head data are not available as of mid-2026 — the trials studied retatrutide against placebo or active control in different populations. Indirect comparison of Phase 2 figures: retatrutide at 12 mg/48 wk produced −24.2% body weight versus tirzepatide's Phase 3 maximum of approximately −22.5% at its highest dose in the obesity trial. A direct active-comparator Phase 3 trial is ongoing within the TRIUMPH program. See retatrutide vs tirzepatide for a full data comparison.
How much retatrutide per week?
In the Phase 2 obesity trial, once-weekly doses of 1, 4, 8, and 12 mg were studied via subcutaneous injection [1]. The 12 mg once-weekly arm produced the largest weight-loss effect (−24.2% at 48 weeks). These are study-design facts — the doses the trial administered — not prescribing guidance. No approved dose for any individual exists.
How to mix retatrutide with bacteriostatic water?
There is no validated protocol for mixing retatrutide with bacteriostatic water. Retatrutide was supplied in trials as a pre-prepared solution — not as a lyophilized powder requiring reconstitution. Gray-market research-labeled vials may be lyophilized, but no reconstitution standard exists, and independent analyses of similar gray-market peptides have found contaminants including truncated sequences and non-sterile preparations [1]. This site does not provide reconstitution instructions.
How to switch from tirzepatide to retatrutide?
No clinical protocol for switching between tirzepatide and retatrutide has been published, as retatrutide is not approved and is not available as a prescription product. Tirzepatide is FDA-approved; retatrutide is investigational. Any transition between pharmacologically active incretin agents would require medical supervision to manage overlapping receptor activity and potential GI, cardiac, and glycemic effects. This site does not provide clinical transition guidance.
Is retatrutide a GLP-3?
No. "GLP-3" is a popular misnomer. There is no GLP-3 receptor. Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors — three distinct hormone receptor systems [3][6]. The GLP-1, GIP, and glucagon receptors are all class-B G-protein-coupled receptors but are encoded by different genes and bind different endogenous hormones. The "GLP-3" label appears to have emerged from confusion about incretin receptor numbering; it has no pharmacological basis.
Is retatrutide available?
Not as an approved prescription product. Retatrutide is in Phase 3 trials and is not available by prescription or through any licensed pharmacy as of mid-2026 [7]. A gray market of research-labeled material exists but such products carry no quality assurance, no verified identity, no sterility guarantee, and are subject to FDA enforcement action [1]. Clinical trial enrollment is possible through ClinicalTrials.gov.
What is retatrutide used for?
In Phase 2 trials retatrutide has been studied for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). Phase 3 trials are evaluating it in obesity, type 2 diabetes, cardiovascular disease, and chronic kidney disease [9][10]. It has no approved use — it is investigational. A 2025 review in Biomolecules characterizes its potential as a new standard for obesity pharmacotherapy pending Phase 3 results [6].
What receptors does retatrutide target?
Three: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Cryo-EM structural studies confirmed simultaneous triple engagement at near-atomic resolution [3]. Relative potency is 8.9× endogenous GIP at GIPR, 0.4× endogenous GLP-1 at GLP-1R, and 0.3× endogenous glucagon at GCGR [3].
Is retatrutide legal?
Retatrutide is not a scheduled controlled substance in the United States as of mid-2026, but it is an unapproved new drug under federal law. Selling, distributing, or administering it outside clinical-trial conditions may violate the Federal Food, Drug, and Cosmetic Act. The FDA has issued enforcement letters against vendors [1]. Regulatory status in other jurisdictions varies; consult local regulatory guidance. WADA has not specifically prohibited GLP-1/GIP/glucagon receptor agonists in the current Prohibited List, but athletes should consult the latest WADA list as investigational agent status can change.
How often do you take retatrutide?
In all Phase 1, 2, and 3 trials studied to date, retatrutide has been administered once weekly via subcutaneous injection [1][2][4]. The approximately 6-day half-life supports once-weekly dosing without significant accumulation gaps between administrations [4]. No other dosing frequency has been evaluated in published literature.
What is the half-life of retatrutide?
Approximately 6 days, based on Phase 1b pharmacokinetic data [4]. The extended half-life is achieved through C20 fatty-diacid acylation, which binds the peptide to albumin (a blood protein) and slows renal and hepatic clearance. A 6-day half-life means once-weekly dosing maintains relatively stable blood concentrations between injections.
How to store retatrutide?
Approved storage conditions for retatrutide do not exist — it has no approved formulation. In clinical trials it was stored per Eli Lilly's investigational drug protocols, which are not publicly available. Gray-market products have no validated storage standard. Peptide-based injectables generally require refrigeration and protection from light, but applying generic peptide storage guidance to an unapproved, unverified product does not constitute safety assurance [1].
Is retatrutide the same as Ozempic?
No. Retatrutide and semaglutide (the active ingredient in Ozempic) are different molecules with different receptor profiles. Semaglutide is a GLP-1 receptor mono-agonist that is FDA-approved for type 2 diabetes and obesity management. Retatrutide is a GIP/GLP-1/glucagon triple agonist that is investigational and not yet approved. The two have not been compared in a head-to-head trial. Phase 2 figures for retatrutide (−24.2% body weight at 12 mg/48 wk) exceed the largest Phase 3 semaglutide figures by several percentage points, but cross-trial comparisons have significant methodological limitations.
Is retatrutide better than semaglutide?
Phase 2 retatrutide figures (−24.2% at 12 mg/48 wk) are numerically larger than the largest Phase 3 semaglutide obesity trial figures. However, no direct head-to-head trial of retatrutide versus semaglutide has been conducted, and cross-trial comparisons are confounded by different populations, endpoints, and durations. Whether retatrutide is "better" by any clinical standard will require head-to-head Phase 3 data, which is not yet available. Retatrutide is also investigational; semaglutide has an established long-term safety and efficacy record from approved-indication use.